Consequently, the failure of bortezomib to reduce SBPs in the present study may reflect the persistence of pro-hypertensive, potentially IgE-producing, ASCs during the development of angiotensin II-induced hypertension, or that alternative mechanisms drive B cell-mediated hypertensive responses. Here, IGHE is linked to hypertensive disorder.